GA
AKRO

General Atlantic’s Akero Therapeutics AKRO Stock Holding History

General Atlantic’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,733,989
Closed -$272M – 15
2025
Q3 		$272M Hold
5,733,989
– – 8.17% 6
2025
Q2 		$306M Buy
5,733,989
+500,000
+10% +$22.7M 8.43% 5
2025
Q1 		$212M Hold
5,233,989
– – 7.11% 5
2024
Q4 		$146M Hold
5,233,989
– – 5.18% 6
2024
Q3 		$150M Hold
5,233,989
– – 4.27% 7
2024
Q2 		$123M Hold
5,233,989
– – 3.86% 8
2024
Q1 		$132M Buy
5,233,989
+3,448,275
+193% +$82.8M 3.07% 9
2023
Q4 		$41.7M Hold
1,785,714
– – 0.6% 18
2023
Q3 		$90.3M Hold
1,785,714
– – 1.39% 13
2023
Q2 		$83.4M Buy
+1,785,714
New +$81.8M 1.31% 12

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

General Atlantic's AKRO Position: Q4 2025 in Review

General Atlantic sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 5,733,989 shares — an estimated $272M sold.

General Atlantic first reported a position in AKRO in Q2 2023 and held it in 10 quarters. The position peaked at $306M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • General Atlantic reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • General Atlantic sold 5,733,989 Akero Therapeutics shares in Q4 2025, an estimated $272M.
  • General Atlantic first reported a position in Akero Therapeutics in Q2 2023 and held it in 10 quarters.
  • General Atlantic's Akero Therapeutics position peaked at $306M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on General Atlantic's 13F filing for Q4 2025, filed 17 Feb 2026.